F.L.Putnam ESG Core US SMA (S:0P0001QB33)
25.80
0.00 (0.00%)
USD |
Apr 30 2024
Returns Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Key Stats
| Maximum Management Fee | Annualized Total Returns Since Inception (Daily) | Alpha (vs Category) (3Y) | Forecasted Dividend Yield |
|---|---|---|---|
| Upgrade | Upgrade | Upgrade | Upgrade |
| Total Market Value (Net) | Beta (vs Category) (3Y) | Max Drawdown (Since Inception) | Fwd Dividend Yield (Long) |
| Upgrade | Upgrade | Upgrade | Upgrade |
Basic Info
| Investment Strategy | |
| ESG Core US Equity is a core domestic equity strategy employing integrated ESG analysis and fundamental research, a combination that is helpful when evaluating the long-term sustainability of revenue and earnings growth and provides a full picture of potential risks. The strategy tilts toward higher-scoring ESG companies and seeks to avoid companies with potentially significant environmental, product, or brand-damaging liabilities. |
| General | |
| Security Type | Separately Managed Account |
| Equity Style | Large Cap/Growth |
| Fixed Income Style | -- |
| Broad Asset Class | US Equity |
| Broad Category | Equity |
| Category Name | Large Blend |
| Category Index | Russell 1000 TR USD |
| Global Category Name | US Equity Large Cap Blend |
| YCharts Categorization | US Large Cap Blend |
| YCharts Benchmark | S&P 500 Total Return (^SPXTR) |
| Fund Owner Firm Name | F.L.Putnam Investment Management |
| Prospectus Benchmark Index | |
| S&P 500 | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^SPXTR | 100.0% |
| Manager Tenure | |
| Steven Violin | 7.74 yrs |
Annual Total Returns Versus Peers
As of April 30, 2024.
Asset Allocation
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
| Microsoft Corp | 7.97% | 467.56 | 1.47% |
| Alphabet Inc Class A | 4.90% | 190.60 | 2.57% |
| Apple Inc | 3.80% | 226.34 | 2.16% |
| Amazon.com Inc | 3.67% | 200.00 | 1.22% |
| Visa Inc Class A | 3.29% | 270.36 | 0.51% |
| Broadcom Inc | 3.21% | 1703.31 | -1.50% |
| AstraZeneca PLC ADR | 3.16% | 77.34 | 0.70% |
| Lam Research Corp | 3.04% | 1087.80 | 0.47% |
| UnitedHealth Group Inc | 2.94% | 488.01 | -0.38% |
| NVIDIA Corp | 2.73% | 125.83 | -1.91% |
Fees & Availability
| Fees | |
| Negotiable Fee | No |
| Administrative Fee | -- |
| Maximum Management Fee | Upgrade |
| Prospectus Custodian Fee | -- |
| Trustee Fee | -- |
| Purchase Details | |
| Open to New Investors |
|
| Open to Existing Investors |
|
| Minimum Initial Investment | -- |
| Minimum Subsequent Investment | -- |
Basic Info
| Investment Strategy | |
| ESG Core US Equity is a core domestic equity strategy employing integrated ESG analysis and fundamental research, a combination that is helpful when evaluating the long-term sustainability of revenue and earnings growth and provides a full picture of potential risks. The strategy tilts toward higher-scoring ESG companies and seeks to avoid companies with potentially significant environmental, product, or brand-damaging liabilities. |
| General | |
| Security Type | Separately Managed Account |
| Equity Style | Large Cap/Growth |
| Fixed Income Style | -- |
| Broad Asset Class | US Equity |
| Broad Category | Equity |
| Category Name | Large Blend |
| Category Index | Russell 1000 TR USD |
| Global Category Name | US Equity Large Cap Blend |
| YCharts Categorization | US Large Cap Blend |
| YCharts Benchmark | S&P 500 Total Return (^SPXTR) |
| Fund Owner Firm Name | F.L.Putnam Investment Management |
| Prospectus Benchmark Index | |
| S&P 500 | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^SPXTR | 100.0% |
| Manager Tenure | |
| Steven Violin | 7.74 yrs |
Fundamentals
| Number of Holdings | Upgrade |
| Stock | |
| Weighted Average PE Ratio | 24.52 |
| Weighted Average Price to Sales Ratio | Upgrade |
| Weighted Average Price to Book Ratio | Upgrade |
| Weighted Median ROE | Upgrade |
| Weighted Median ROA | Upgrade |
| Forecasted Dividend Yield | Upgrade |
| Forecasted PE Ratio | Upgrade |
| Forecasted Price to Sales Ratio | Upgrade |
| Forecasted Price to Book Ratio | Upgrade |
As of March 31, 2024
Fund Details
| Key Dates | |
| Inception Date | 10/4/2016 |
| Last Annual Report Date | 12/31/2023 |
| Last Prospectus Date | -- |
| Attributes | |
| Index Fund | No |
| Inverse Fund | No |
| Leveraged Fund | No |
| Fund of Funds | No |
| Currency Hedged Fund | No |
| Synthetic Replication Fund | No |
| Has Dividend Investment Plan | No |
| Socially Responsible Fund | No |